ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients

Featured News

  • 13 Jan 2014 4:58 PM | Christopher McCoy
    We would like to follow our members.  Please email us at sidptwit@gmail.com to send us your name on Twitter.  Follow us at SIDPharm, visit SIDP Twitter site
  • 06 Dec 2013 4:03 PM | Christopher McCoy
    Sovaldi is one of the more anticipated oral agents available to treat certain types of HCV infection, in some cases without the need for co-administration of interferon.  Unlike other recently available agents which have failed to meet the anticipated benefit, the drug may be combined with an all oral regimen and early signs indicate a low pill burden with lesser adverse effects. 
  • 05 Dec 2013 8:19 PM | Christopher McCoy
    You still have time, see our event listings for details.  With all the new vaccines available, document your clinical experience. Also, just released today are the IDSA guidelines for vaccination of immunocompromised patients.
  • 20 Nov 2013 4:11 PM | Christopher McCoy
    As in past years, the effort coordinates the work of CDC’s Get Smart: Know When Antibiotics Work campaign, state-based appropriate antibiotic use campaigns, non-profit partners, and for-profit partners during a one week observance of antibiotic resistance and the importance of appropriate antibiotic use. Its geared across healthcare settings so whether you practice in an ambulatory setting or a large teaching institution, there is something for you to engage in.  Some of you may have sat in on the live teleconference on Tuesday.  Others may want to particpate in the program on Friday on Twitter.
    • Friday, November 22, 2013 at 1 p.m. EST
      Twitter Chat with @CDCgov on antibiotic resistance and appropriate antibiotic use
      ParticipateExternal Web Site Icon with hashtag #SaveAbx

    Find info on the website to share with patients, for continuing education needs, for flyers related to stewardship activities. 

  • 20 Nov 2013 4:07 PM | Christopher McCoy

    New toolkit aims to decrease central line-associated bloodstream infections (CLABSI)

    A new toolkit, "Preventing Central Line-Associated Bloodstream Infections – Useful Tools, An International Perspective," developed by The Joint Commission, Joint Commission Resources and Joint Commission International is now available to help healthcare organizations implement practices to reduce these preventable infections that threaten lives and increase healthcare costs. The toolkit is a companion piece to a 2012 monograph with the same title, but subtitled, "A Global Challenge, A Global Perspective." The resources cover central lines only and are designed for healthcare personnel who insert and care for intravascular catheters and who are responsible for the surveillance, prevention and control of infections in all healthcare settings. For more information, go to the website.

  • 23 Sep 2013 5:23 PM | Christopher McCoy

    The four episode series, you can choose how many you want, addresses clinical effectiveness of the vaccine, new vaccine formulations including the quadrivalent vaccine and proposed ACIP changes.  Each is good for 0.5 ACPE CEU.  For details and a link, visit our Educational Resources page.

    Clinical Update for the 2013-2014 Flu Season  - Expert Interview Digest

  • 23 Sep 2013 5:17 PM | Christopher McCoy
    A reported record number of attendees were present at the annual meeting in Denver.  Full details of the half day meeting of lectures, awards and the reception will be forthcoming.  The new board was installed with Joseph Kuti of Hartford Hospital and the Center for Antiinfective Research and Development taking the role as incoming President.  For a full review of the board roster visit the About Us tab.  Don't forget to sign up for committees in the meantime.
  • 07 Aug 2013 9:16 AM | Russell Benefield

    The SIDP-endorsed Rapid Diagnostic Test certification program is being offered in Lansing, Michigan on October 1st and 2nd, and a train-the-trainer program is scheduled for October 2nd.  These programs will benefit any pharmacist that is interested in learning about Rapid Diagnostic Tests and their use in pharmacy practice.  Content from the programs will also benefit those looking to incorporate this material into their pharmacy curriculum.  Interested participants may register via the link below.  For more information contact Michael Klepser (klepserm@ferris.edu).

     

    Program Registration: http://michiganpharmacists.org/eventDetails.php?x=1029 

  • 10 May 2013 1:00 PM | Russell Benefield

    Washington D.C. – U.S. Senators Kirsten Gillibrand, Dianne Feinstein, and Susan Collins today introduced bipartisan legislation aimed at combating antimicrobial drug resistance.  The Antimicrobial Data Collection Act calls for increased data collection by the Food and Drug Administration (FDA), enhanced transparency and public awareness of antimicrobial drug use in agriculture and strengthened FDA accountability regarding unsafe antimicrobial drug use. The Centers for Disease Control estimates that, each year, antimicrobial resistance costs taxpayers $20 billion in excessive healthcare and results in more severe illness and a greater risk of death for infected patients. Currently, there are at least six multidrug resistant major human pathogens. 

     

    “Antimicrobial resistance is a public health concern that needs to be adequately addressed,” said Senator Gillibrand.  “Increased data collection, transparency, and accountability are part of a comprehensive solution that will help protect American citizens from drug resistant microbes, saving lives and tax dollars.” 

    “Our bill would not create any new reporting requirements for drug companies, feed mills, or farmers.  It would only require the FDA to provide more transparency in reporting the antimicrobial data which is already being reported to it,” said Senator Collins.

     

    Specifically, the legislation requires a pilot program to look into new data sources on antibiotics used on food producing animals.  The FDA will create a comprehensive data collection strategy, based on the new data sources, in order to increase data availability to the public, increasing the FDA’s transparency.  The FDA’s increased transparency would shed light on information about antimicrobial drugs used in agriculture that are not currently made public, such as dosage form, strength and targeted animals.  The Government Accountability office will then audit the FDA to determine if the data collection for antimicrobial resistance programs is effective in protecting public health.

     

    SIDP strongly supports the ADC Act and encourages members to contact their congressmen and women to promote passage of this bill.

       

    Summary of Antimicrobial Data Collection Act Bill                                                         

    1. Increase Data Collection by the Food & Drug Administration (FDA)
      • Requires a pilot program to look at new data sources to collect more data on antibiotic use in food animals. 
      • Requires FDA to then develop a comprehensive data collection strategy to increase data available to the public and scientists. 
    2. Enhance Transparency and Public Data on Antimicrobial Drug Use in Agriculture
      • Requires FDA to make more detailed information available to the public on antimicrobial drugs used in agriculture which is not currently made public, such as dosage form, strength, and target animals.
    3. Strengthen Accountability for the Food & Drug Administration to Protect Public Health
      • Requires FDA to implement and annually publically evaluate compliance with its draft policies to reduce injudicious antimicrobial use, including those used for growth promotion purposes. 
      • Requires a GAO audit to determine if FDA data collection and antimicrobial resistance programs are effective for protecting public health. 
  • 29 Apr 2013 2:20 PM | Russell Benefield

    SIDP is soliciting ID pharmacotherapy research proposals from SIDP members who qualify as young investigators [£5 years from completion of their terminal training (e.g., residency, fellowship, graduate degree)].  The primary purpose of the research award is to provide funding for research projects that will contribute to the further development of the principal investigator’s research career and improve their competitiveness for future extramural funding.  Favorable consideration will be given to research proposals which focus on current pharmacotherapy issues surrounding the prevention and management of infectious diseases.  Applications must be submitted no later than 5PM E.S.T on Friday, August 9, 2013.

     

    Application instructions:

    2013 YIRA RFP

Membership gives you more

  • Access exclusive opportunities
  • Connect with colleagues
  • Attend networking events

JOIN TODAY


Society of Infectious Diseases Pharmacists • 121 W. State Street, Geneva, IL 60134
(331) 248-7888 sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software